Heat shock protein 60 as a novel therapeutic target for diabetes and rheumatoid arthritis (HSPFORTHERAPY)

Objective

Heat shock proteins are antigens of immune responses in autoimmunity. In experimental models they suppress inflammation and in clinical trials in diabetes and arthritis hsp60 has a proven therapeutic potential. We propose to analyse the underlying mechanisms by monitoring immunity to hsp60 in the models, in patients and during hsp60 peptide trials, with respect to both the adaptive and the innate part of the immune system.

Fields of science

• medical and health sciences › clinical medicine › rheumatology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › basic medicine › immunology

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases

Call for proposal

Data not available

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UTRECHT UNIVERSITY

Address

Yalelaan 1
3584 CL Utrecht
Netherlands

Participants (5)

DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT E.V.

Germany

Address

Auf'm Hennekekamp 65
40225 Duesseldorf

PEPTOR LTD

Israel

Address

Kyriat Weizmann, Building 16
76326 Rehovot

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

Address

Hills Road Addenbrooke's Nhs Trust 5
CB2 2QQ Cambridge

UNIVERSITY MEDICAL CENTRE UTRECHT

Netherlands

Address

Lundlaan 6
3584EA Utrecht

WEIZMANN INSTITUTE OF SCIENCE

Israel

Address

Herzel Street 2
76100 Rehovot